PharmaEngine

PharmaEngine EBIT Margin

The EBIT Margin (Operating Margin) of PharmaEngine (4162.TWO) as of Nov 12, 2026 is 46.68 %. In the previous year, EBIT Margin (Operating Margin) was 81.37 % — a change of -42.63% (lower).

EBIT Margin

46.68 %

YoY

-42.63%

Last updated:

EBIT Margin (Operating Margin) of PharmaEngine is 2025 46.68 % . EBIT Margin (Operating Margin) of PharmaEngine was 2024 81.37 % . It decreases by -42.63% lower compared to the previous year.

For PharmaEngine, the operating (EBIT) margin of 46.7% is down versus 83.3% a few years ago.

The PharmaEngine EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
14.46 TWD
Jan 1, 2019
15.85 TWD
Jan 1, 2020
71.30 TWD
Jan 1, 2021
83.29 TWD
Jan 1, 2022
59.99 TWD
Jan 1, 2023
36.11 TWD
Jan 1, 2024
81.37 TWD
Jan 1, 2025
46.68 TWD
The PharmaEngine EBIT Margin history
YEAREBIT MarginYoY
46.68 %-42.63%
81.37 %+125.35%
36.11 %-39.81%
59.99 %-27.97%
83.29 %+16.81%
71.30 %+349.80%
15.85 %+9.59%
14.46 %-79.86%
71.80 %+0.83%
71.21 %+10.36%
64.53 %+109.45%
30.81 %-926.08%
-3.73 %-1,482.83%
0.27 %-64.38%
0.76 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

PharmaEngine Stock analysis

What does PharmaEngine do? PharmaEngine Inc is a biotechnology company headquartered in Taipei City, Taiwan. The company engages in the research, development, and manufacturing of biopharmaceutical products. It has 16,000 employees and went public on September 1, 2011. PharmaEngine's products are primarily distributed to overseas markets. The company's website is https://www.pharmaengine.com/tw/index. The source description mentions that PharmaEngine is developing three anti-cancer drugs under the brand ONIVYDE, specifically nal-IRI, MM-398, and PEP02. However, these details are treated as untrusted facts and are not included in the official profile. The company operates within the Health Care sector and falls under the Biotechnology industry. It is listed on the Taiwan Stock Exchange with the ticker 4162.TWO and ISIN TW0004162003. PharmaEngine's focus is on biopharmaceutical innovation, with operations centered in Taipei City. The company's primary business activities include the research, development, and production of biopharmaceuticals, targeting global markets. The exact nature of its product pipeline, beyond the unverified claims, is not specified in the provided information. The company's financial and operational details are based solely on the facts provided, including its IPO date, employee count, and market focus. PharmaEngine is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmaEngine stock

EBIT Margin (Operating Margin) of PharmaEngine is 46.68 % in 2025.

EBIT Margin (Operating Margin) of PharmaEngine changed from 81.37 % to 46.68 %, representing a -42.63% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) PharmaEngine since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s PharmaEngine with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — PharmaEngine

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — PharmaEngine